TeriFort 1+ Study: Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study (TeriFort 1+)
Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study
This study aims to evaluate the clinical effect, as reported by physicians, of an extensively hydrolyzed formula in young children aged 1~3 years with diagnosed with or highly suspected CMPA in a real-world clinical practice setting. The study will also evaluate the growth parameters, stool frequency and consistency, formula intake volume, gastrointestinal tolerance (including fussiness, flatulence, colic) and sleep disturbances, and any adverse events that may arise during the intervention period. This is a prospective, single-arm study including 50 young children at 1 hospital in China. Each participant will be followed for 90 days.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
Cow's milk protein allergy (CMPA) is one of the most common food allergy in infancy and early childhood. The global overall prevalence ranges from 0.5% to 3% , and in some regions it can be as high as 4.9%. Currently, there are no nationwide epidemiological survey data on CMPA in China. However, local studies conducted in Chongqing, Hangzhou, and Zhuhai have reported a prevalence of 0.83% ~ 3.5% in infants aged 0 ~ 2 years. The pathogenesis of CMPA mainly includes IgE-mediated immediate-type hypersensitivity, non-IgE-mediated delayed-type hypersensitivity, and mixed-type reactions mediated by both mechanisms. Clinical manifestations may involve multiple organs and systems, including the skin, gastrointestinal tract, and respiratory tract. Dietary avoidance of cow's milk protein continues to be the main therapeutic approach, utilizing extensively hydrolyzed or amino acid-based formulas as determined by the degree of allergy.
Ages 1 ~ 3 years represent a critical window for the persistence of allergic symptoms and disease resolution in toddlers; approximately 85% ~ 90% of children with CMPA achieve clinical tolerance by around 3 years of age. Meanwhile, the age group of 1 ~ 3 years is also a critical period for dietary transition and the establishment of immune tolerance, during which children are particularly vulnerable to nutritional deficiencies. Therefore, special attention should be given to this age group, so that early diagnosis and appropriate interventions can be implemented to mitigate the impact of the disease on growth and development.
This is a prospective, longitudinal, single-arm study conducted at 1 hospital in China. The study will enroll young children aged 1~ 3 years with diagnosed with or highly suspected CMPA. Each participant will be followed for 90 days after the initiation of the investigational product. Parents or legal guardians will complete questionnaires regarding symptoms, gastrointestinal function, and product acceptability, while investigators will record clinical symptoms and anthropometric data using an electronic case report form (eCRF).
Collected data will include:
- Sociodemographic and baseline characteristics: sex, birth weight and length, gestational age, and family history of allergy.
- Anthropometric parameters: weight, length, and head circumference.
- Clinical assessments: Modified CoMiSS, SCORAD, and BSFS scores.
- Parent-reported outcomes: IGSQ-13, FAQL-PB, BISQ scores,and acceptability/satisfaction surveys.
- Safety outcomes: adverse events and concomitant medications.
A healthy reference group will include, which underwent only the modified CoMiSS assessment without exposure to the investigational product or involvement in efficacy/safety analyses, yielding normative reference benchmarks for the healthy population.
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 不适用
联系人和位置
学习联系方式
学习联系方式
- 姓名:Qintong Duan
- 电话号码:+8613782669477
- 邮箱:duanqintong@mengniu.cn
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200000
- Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine
-
接触:
- Chenwai Xiao
- 电话号码:+8619121378960
- 邮箱:xiaochenwai@scmc.com.cn
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
12 months≤ Age <36 months at enrollment.
-
Born at term at 37 ~ 42 weeks of gestation, with birth weight 2,500~4,000g.
-
Diagnosed with or highly suspected mild-to-moderate CMPA by a physician, meeting any of the following prior to enrollment:
- Positive serum cow's-milk-specific IgE (sIgE) >0.35 kUA/L (>0.7 kIU/L), combined with a detailed medical history; or a positive skin prick test (SPT);
- Positive result from a cow's milk protein elimination-challenge test;
- A documented medical history confirming CMPA within the 2 weeks prior to enrollment.
-
Hospitalization is not required and home intervention is considered appropriate by the investigator.
-
Written informed consent signed by a parent or legal guardian.
Exclusion Criteria:
- History of severe cows-milk-induced allergic reaction, such as anaphylactic shock.
- Underlying disease or history that may increase risk or affect gastrointestinal tolerance, growth, or development, including chronic systemic disease, congenital heart disease, chronic inflammatory bowel disease, malignant tumor, gastrointestinal malformation, or major congenital malformation.
- Laboratory abnormalities judged by the investigator to make participation inappropriate.
- Use of an extensively hydrolyzed formula or amino-acid formula within the preceding month.
- Participation in another interventional clinical trial within the preceding 90 days or currently.
- Inability to complete scheduled study visits
- Known intolerance to another ingredient in the study formula
- Any other condition judged inappropriate by the investigator.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Diagnosed with or highly suspected CMPA: Extensively Hydrolyzed Formula intervention
|
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in investigator-reported allergy symptom scores
大体时间:Baseline, Day 30 ± 5, Day 90 ± 7
|
Change from baseline to D30 and D90 in investigator-assessed allergy symptoms in toddlers with diagnosed with or highly suspected cow's milk protein allergy, measured using four instruments. |
Baseline, Day 30 ± 5, Day 90 ± 7
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in investigators measured or parent/caregiver-reported allergy symptom scores
大体时间:Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
Change from baseline to D30, D60 and D90 in investigators measured or parent/caregiver-reported symptoms, which will be analyzed according to improvement (reduction in score) or no improvement. |
Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
|
Change in z-scores for weight, length/height, and head circumference
大体时间:Baseline, Day 30 ± 5, Day 90 ± 7
|
Change in z-scores for weight, length/height, and head circumference calculated according to World Health Organization (WHO) growth standards. Differences between baseline, D30 and D90 will be summarized using descriptive statistics. |
Baseline, Day 30 ± 5, Day 90 ± 7
|
|
Change in stool characteristics
大体时间:Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
Parent-reported stool characteristics (consistency and color), stool frequencies and stool types will be summarized for each visit. |
Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
|
Stool Samples Test Results
大体时间:Baseline, Day 30 ± 5, Day 90 ± 7
|
Abnormalities in routine stool examination and fecal occult blood test. |
Baseline, Day 30 ± 5, Day 90 ± 7
|
|
Change in parental quality of life related to children allergy
大体时间:Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
Change in the Food Allergy Quality of Life-Parental Burden Questionnaire (FAQL-PB) score from baseline to Day 30, Day 60 and day 90. Improvement will be defined as a reduction in the total score. Descriptive statistics and frequencies of improvement will be presented. |
Baseline, Day 30 ± 5, Day 60 ± 7, Day 90 ± 7
|
|
Parental satisfaction with the investigational product
大体时间:Day 90 ± 7
|
Parent- or caregiver-reported satisfaction with the investigational product. |
Day 90 ± 7
|
|
Dietary intake
大体时间:Baseline, Day 30 ± 5, Day 90 ± 7
|
Assessment of dietary intake, including food categories and quantities (by weight), at baseline, on Day 30, and on Day 90 of the intervention. |
Baseline, Day 30 ± 5, Day 90 ± 7
|
|
Adverse Events and Concomitant Medications
大体时间:From first intervention to Day 90 ± 7
|
Incidence, severity, and causal attribution to the study product of AEs and SAEs, together with concomitant medication use, throughout the study period. |
From first intervention to Day 90 ± 7
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.